# Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

Study · id `cardio:ct-nct06362746` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06362746](<https://clinicaltrials.gov/study/NCT06362746>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06362746

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 486 participants.

## Technical summary

Registry record NCT06362746. Randomized; double masking; primary purpose treatment. Start 2024-05-23 (actual); primary completion 2028-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 486 participants (planned count; ClinicalTrials.gov record NCT06362746, source copy `cardio:ctgov-nct06362746-2025-12-05`, retrieved 2026-10-31)
- Started: 2024-05-23 (actual) (ClinicalTrials.gov record NCT06362746, source copy `cardio:ctgov-nct06362746-2025-12-05`, retrieved 2026-10-31)
- Primary completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT06362746, source copy `cardio:ctgov-nct06362746-2025-12-05`, retrieved 2026-10-31)
- Completion: 2028-12-01 (anticipated) (ClinicalTrials.gov record NCT06362746, source copy `cardio:ctgov-nct06362746-2025-12-05`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT06362746, source copy `cardio:ctgov-nct06362746-2025-12-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06362746-2025-12-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
- Condition: Pulmonary Embolism
- Intervention (Drug): Non-immunogenic recombinant staphylokinase
- Intervention (Drug): Placebo
- Lead sponsor: Supergene, LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Supergene, LLC (`cardio:org-supergene-llc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE (`cardio:pubmed-39454884`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 10c78d8643e6605f88a95508b8028a884242775d04d3c33f5c7c943917e0523f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
